Den Europæiske Union - estisk - EMA (European Medicines Agency)

infai, institut für biomedizinische analytik nmr-imaging gmbh - urea (13c) - breath tests; helicobacter infections - diagnostilised ained - helicobacter test infai võib kasutada in vivo diagnoosi gastroduodenal helicobacter pylori infektsioon:täiskasvanutele;noorukid, kes on tõenäoliselt ka maohaavandi haigus. helicobacter test infai lastele vanuses kolm kuni 11 aastat võib kasutada in vivo diagnoosi gastrduodenal helicobacter pylori infektsioon:hindamine edu likvideerimise ravi, või;kui invasiivsete teste ei saa teha, või;kui on discordant tulemused, mis tulenevad invasiivsete testid. see ravim on mõeldud ainult diagnostiliseks kasutamiseks.

Den Europæiske Union - estisk - EMA (European Medicines Agency)

advanz pharma limited - obeticholic happega - maksatsirroos, sapiteet - vere ja maksa ravi - ocaliva on näidustatud esmase sapiteede kolangiit (ka esmane maksatsirroos) koos ursodeoxycholic hape (udca) täiskasvanutel ja kes ei udca või monoteraapiana täiskasvanud ei talu udca.

Den Europæiske Union - estisk - EMA (European Medicines Agency)

astrazeneca ab - osimertinib mesilate - kartsinoom, mitteväikerakk-kopsu - muud antineoplastilised ained, protein kinase inhibiitorid - tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations- the first-line treatment of adult patients nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc. tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations. - the first-line treatment of adult patients with locally advanced or metastatic nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc.

Den Europæiske Union - estisk - EMA (European Medicines Agency)

n.v. organon - ganireliks - reproductive techniques, assisted; ovulation induction; infertility, female - hüpofüüsi ja hüpotaalamuse hormoonid ja analoogid - ennetamine enneaegne luteiniseerivat hormooni järsk viiakse läbi kontrollitud munasarjade hüperstimulatsiooni viljastamist. kliinilistes uuringutes kasutati orgalutran koos rekombinantse inimese folliikuleid stimuleeriv hormoon või corifollitropin alfa, jätkuv folliikuleid stimuleeriv.

Den Europæiske Union - estisk - EMA (European Medicines Agency)

torbet laboratories ireland limited - urea (13c) - breath tests; helicobacter infections - diagnostilised ained - see ravim on mõeldud ainult diagnostiliseks kasutamiseks. in vivo diagnoosi gastroduodenal helicobacter pylori h. pylori) infektsioon.

Den Europæiske Union - estisk - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vaktsiinid - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. kasutamist see vaktsiin peaks olema kooskõlas ametlike soovitustega.

Den Europæiske Union - estisk - EMA (European Medicines Agency)

chemical works of gedeon richter plc. (gedeon richter plc.) - ganirelix acetate - reproductive techniques, assisted; ovulation induction; infertility, female - hüpofüüsi ja hüpotaalamuse hormoonid ja analoogid - prevention of premature luteinising hormone (lh) surges in women undergoing controlled ovarian hyperstimulation (coh) for assisted reproduction techniques (art).

Estland - estisk - Ravimiamet

norbrook laboratories limited - doramektiin - kriipsulahus - 5mg 1ml 250ml 1tk; 5mg 1ml 20000ml 1tk; 5mg 1ml 5000ml 1tk; 5mg 1ml 2500ml 1tk; 5mg 1ml 10000ml 1tk

Estland - estisk - Ravimiamet

norbrook laboratories limited - doramektiin - kriipsulahus - 5mg 1ml 5000ml 1tk; 5mg 1ml 2500ml 1tk; 5mg 1ml 1000ml 1tk; 5mg 1ml 10000ml 1tk; 5mg 1ml 250ml 1tk

Estland - estisk - Ravimiamet

sandoz pharmaceuticals d.d. - doksorubitsiin - infusioonilahuse kontsentraat - 2mg 1ml 50ml 1tk; 2mg 1ml 25ml 1tk; 2mg 1ml 5ml 1tk